Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far

Robert P. Baughman, Oksana A. Shlobin
European Respiratory Journal 2017 50: 1701725; DOI: 10.1183/13993003.01725-2017
Robert P. Baughman
1Dept of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bob.baughman@uc.edu
Oksana A. Shlobin
2Pulmonary Vascular Disease Program, Inova Fairfax Hospital, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

More evidence that sarcoidosis patients with pulmonary hypertension respond to therapy http://ow.ly/H40c30fetN4

Patients with advanced sarcoidosis may develop pulmonary hypertension for a variety of reasons [1]. One of the earlier papers noting the incidence and severity of this problem came from the clinic run by Gianfranco Rizzato in Milan [2]. Despite the well documented association noted in that article, there were very few reports of sarcoidosis-associated pulmonary hypertension (S-APH) until 20 years later. Over the past 10 years, reports regarding S-APH have come from the USA [3–5], Europe [1, 6, 7] and Japan [8]. These studies found that S-APH was most frequently seen patients with fibrotic disease and was associated with increased mortality [9, 10].

The majority of the previously published studies were relatively small and usually reported data on patients followed at individual sites. In this issue of the European Respiratory Journal, Boucly et al. [11] report on the features and outcomes of S-APH in patients enrolled in the French Pulmonary Hypertension Registry. This paper provides data on a large group of patients followed over a 10-year period. The authors provide descriptive data on the initial presentation and outcomes of the 126 cases with moderate-to-severe S-APH after an average of 6 months of various treatments, including survival statistics as well as information about changes in haemodynamics and 6 min walking distance (6MWD). Therapy included both immunosuppressive medications for the underlying sarcoidosis as well as pulmonary hypertension directed treatment. Although not a randomised study, the large number of patients included in this report provides important insights into the role of treatment of S-APH.

11 patients were treated with anti-inflammatory therapy alone including three S-APH patients with radiographic stage 1 disease and evidence of extrinsic compression of the pulmonary arteries by imaging. All three had an improvement in their haemodynamics with treatment. These patients all had increased 2-fluoro-2-deoxy-d-glucose (FDG) uptake on positron emission tomography (PET) prior to therapy. Increased FDG uptake has been shown to be a marker for response to immunosuppressant therapy for sarcoidosis [12–14]. Boucly et al. [11] recommend performing PET scanning routinely to assess the role of immunosuppressive therapy for all S-APH patients. Given the cost and radiation risk of PET scanning, further studies need to be performed before this can become a standard of care. However, the cost of PET scanning is potentially outweighed by the benefit of identifying those patients in whom using immunosuppressive therapy alone is needed to treat their S-APH.

In the French group, pulmonary hypertension directed therapy was administered to three quarters of the patients. While there was no specific protocol for therapy, the most commonly used agents were endothelial receptor antagonists or phosphodiesterase-5 inhibitors. After a median of 4 months of therapy, repeat haemodynamics and 6MWD were measured. There was a significant improvement in mean pulmonary artery pressure and pulmonary vascular resistance, similar to the data reported in prior studies [15–18]. Interestingly, there was no significant change in 6MWD. An improvement in haemodynamics with little change in 6MWD has been noted in two prospective clinical trials that evaluated S-APH patients after 4 months of therapy [15, 16]. Another study did report that some patients had improvement in their 6MWD after a median of 14 months treatment [17]. That study found that only those patients with none to moderate impairment in vital capacity had an improvement in their 6MWD. In the current French registry report, there was no change in 6MWD for any level of vital capacity impairment.

This finding highlights one of the problems with treatment of S-APH. What should a treating physician use to assess response to therapy? Similarly, should 6MWD be used as an end-point in future S-APH treatment trials? While there is increasing evidence that pulmonary hypertension directed therapy improves haemodynamics, the data on change in 6MWD is less clear. Baseline reduced 6MWD has been repeatedly reported in patients with S-APH [5, 19]. In the current French study, the 6MWD at presentation was independently associated with mortality. In sarcoidosis, changes in 6MWD may be influenced by multiple factors including parenchymal lung disease, cardiac disease, skeletal muscle involvement and sarcoidosis-associated fatigue [19], thus making it a suboptimal study end-point. Future studies of potential therapies for S-APH should be designed with this in mind. For proof of physiological plausibility of a drug as an effective treatment choice for S-APH, a shorter phase one or two clinical trial evaluating changes in haemodynamics after 3–4 months of treatment may be adequate. However, to determine the efficacy of a drug for changing the natural course of S-APH a larger trial would need to be performed. In group 1 pulmonary arterial hypertension, the time until clinical worsening has been shown to be improved by pulmonary hypertension directed therapy [20, 21], and a composite end-point that enables disease worsening to be captured through a number of objective measures may be a better choice for future long term clinical trials in S-APH.

The study by Boucly et al. [11] confirms data from prior studies about the reduced survival of sarcoidosis patients who develop pulmonary hypertension [22]. In this report, the 3- and 5-year survival rates were 74% and 55% respectively, similar to previously published papers [10, 18]. In a recent report, a Cox proportional hazards regression model found the presence of pulmonary hypertension to be an independent predictor of mortality from sarcoidosis [23]. However, it remains unclear whether or not S-APH is an adaptive phenomenon and a surrogate for other deleterious aspects of the disease. Although S-APH is clearly associated with worse outcomes, it still remains unproven that targeted treatment will result in improved outcomes. Therefore, the need to identify treatments for S-APH which not only improve haemodynamics but also delay progression of the disease is crucial. A current trial of riociguat to treat S-APH is an example of the types of trials needed in this area [24].

Disclosures

Supplementary Material

ERJ-01725-2017_Baughman

ERJ-01725-2017_Shlobin

Footnotes

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received August 22, 2017.
  • Accepted August 23, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Nunes H,
    2. Humbert M,
    3. Capron F
    , et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68–74.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Rizzato G,
    2. Pezzano A,
    3. Sala G
    , et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983; 64: 121–128.
    OpenUrlPubMedWeb of Science
  3. ↵
    1. Sulica R,
    2. Teirstein AS,
    3. Kakarla S
    , et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128: 1483–1489.
    OpenUrlCrossRefPubMedWeb of Science
    1. Baughman RP,
    2. Engel PJ,
    3. Meyer CA
    , et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 108–116.
    OpenUrlPubMedWeb of Science
  4. ↵
    1. Bourbonnais JM,
    2. Samavati L
    . Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32: 296–302.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Huitema MP,
    2. Grutters JC,
    3. Rensing BJ
    , et al. Pulmonary hypertension complicating pulmonary sarcoidosis. Neth Heart J 2016; 24: 390–399.
    OpenUrl
  6. ↵
    1. Keir GJ,
    2. Walsh SL,
    3. Gatzoulis MA
    , et al. Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 82–90.
    OpenUrlPubMed
  7. ↵
    1. Handa T,
    2. Nagai S,
    3. Miki S
    , et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129: 1246–1252.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Shorr AF,
    2. Davies DB,
    3. Nathan SD
    . Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922–928.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Baughman RP,
    2. Engel PJ,
    3. Taylor L
    , et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138: 1078–1085.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Boucly A,
    2. Cottin V,
    3. Nunes H
    , et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50: 1700465
    OpenUrlAbstract/FREE Full Text
    .
  11. ↵
    1. Vorselaars AD,
    2. Crommelin HA,
    3. Deneer VH
    , et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J 2015; 46: 175–185.
    OpenUrlAbstract/FREE Full Text
    1. Baughman RP,
    2. Sweiss N,
    3. Keijsers R
    , et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung 2017; 195: 313–322.
    OpenUrl
  12. ↵
    1. Maturu VN,
    2. Rayamajhi SJ,
    3. Agarwal R
    , et al. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 372–380.
    OpenUrl
  13. ↵
    1. Baughman RP,
    2. Culver DA,
    3. Cordova FC
    , et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145: 810–817.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Baughman RP,
    2. Judson MA,
    3. Lower EE
    , et al. Inhaled iloprost for sarcoidosis-associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 110–120.
    OpenUrlPubMedWeb of Science
  15. ↵
    1. Barnett CF,
    2. Bonura EJ,
    3. Nathan SD
    , et al. Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience. Chest 2009; 135: 1455–1461.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Bonham CA,
    2. Oldham JM,
    3. Gomberg-Maitland M
    , et al. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest 2015; 148: 1055–1062.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Baughman RP,
    2. Sparkman BK,
    3. Lower EE
    . Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132: 207–213.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Pulido T,
    2. Adzerikho I,
    3. Channick RN
    , et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Ghofrani HA,
    2. Galie N,
    3. Grimminger F
    , et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330–340.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Shlobin OA,
    2. Nathan SD
    . Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 2012; 39: 1520–1533.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Kirkil G,
    2. Lower EE,
    3. Baughman RP
    . Predictors of mortality in pulmonary sarcoidosis. Chest 2017; in press [https://doi.org/10.1016/j.chest.2017.07.008].
  22. ↵
    Riociguat for sarcoidosis-associated pulmonary hypertension (RioSAPH) https://clinicaltrials.gov/ct2/show/NCT02625558 Date last accessed: August 21, 2017. Date last updated: December 4, 2015.
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 4 Table of Contents
European Respiratory Journal: 50 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far
Robert P. Baughman, Oksana A. Shlobin
European Respiratory Journal Oct 2017, 50 (4) 1701725; DOI: 10.1183/13993003.01725-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far
Robert P. Baughman, Oksana A. Shlobin
European Respiratory Journal Oct 2017, 50 (4) 1701725; DOI: 10.1183/13993003.01725-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • GOLD 2023 streamlines pharmacological treatment
  • The ERS PROFILE.net Clinical Research Collaboration
  • Defining good lung health at population and individual level
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society